Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.40 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | USP14 | P54578 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291691 | 0.89 | CYP4F2 (0.41) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL2296527 | 0.84 | MMP2 (0.47) | CYP4F2CYP4A11CYP4Z1MMP12MMP13 | |
| SCHEMBL2292871 | 0.83 | CYP4Z1 (0.43) | CYP4F2CYP4A11CYP4Z1MMP12MMP13 | |
| SCHEMBL8466268 | 0.82 | CYP4Z1 (0.54) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL8240325 | 0.82 | CYP4Z1 (0.42) | CYP4F2CYP4A11CYP4Z1MMP12MMP13 | |
| SCHEMBL4506493 | 0.79 | CYP4F2 (0.66) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL2295351 | 0.78 | FOLH1 (0.46) | CYP4F2CYP4A11ALOX5LTA4HPTGES | |
| SCHEMBL2294774 | 0.77 | CYP4Z1 (0.39) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL8243544 | 0.76 | CYP4Z1 (0.38) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL6289163 | 0.75 | CTSG (0.41) | CYP4F2CYP4A11CYP4Z1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940811-B1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-1940811-B1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-1940809-B1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-8183271-B2 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183271-B2 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183271-B2 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1940809-A1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1940811-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045370-A1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045370-A1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045366-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045366-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | TNNI3, PC, TNNT2 | CYP4F2 356/4885CYP4A11 54/4885CYP4Z1 1244/4885 |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | TNNI3, TNNT2, FABP3 | CYP4F2 183/4885CYP4A11 831/4885CYP4Z1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.